New drug cocktail shows promise against tough rectal cancers
NCT ID NCT06933251
First seen Mar 13, 2026 · Last updated May 13, 2026 · Updated 11 times
Summary
This study tests whether adding two immune-boosting drugs (PCSK9 and PD-1 inhibitors) to standard chemoradiation can help shrink or eliminate locally advanced rectal cancer. It involves 30 adults aged 18-75 with a specific type of rectal cancer (pMMR/MSS) that has not spread. The goal is to see if this combination improves complete response rates and organ preservation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.